Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330795 · ClinicalTrials.gov registry record · Phase 1
Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03330795 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5 participants.
The verdict
NCT03330795, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched CD3+/CD19+ depleted bone marrow transplant (BMT) is safe and effective for individuals aged 10 through 45 years with the diagnosis of primary immunodeficiency (PID) and end-stage lung disease. The enrollment goal: 8 participants who receive both BOLT and BMT.
Interventions
- BIOLOGICAL CD3/CD19 neg allogeneic BMT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330795
The ClinicalTrials.gov registry entry for NCT03330795 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD3/CD19 neg allogeneic BMT is the first listed.
NCT03330795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03330795 about?
NCT03330795 is a clinical study titled "Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant". The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched CD3+/CD19+ depleted bone marrow transplant (BMT) is safe and effective for individuals aged 10 through 45 years with the diagnosis of primary immunodeficiency (P...
What is the current status of trial NCT03330795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-12-01. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT03330795?
The interventions under investigation include: CD3/CD19 neg allogeneic BMT (BIOLOGICAL).
Who is sponsoring clinical trial NCT03330795?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.